Abstract Details
|
Matthew D. Troyer, MD
(Denali Therapeutics)
PRESENTER |
Dr. Troyer has received personal compensation for serving as an employee of Denali Therapeutics Inc. Dr. Troyer has stock in Denali Therapeutics Inc. Dr. Troyer has stock in Merck & Co., Inc. Dr. Troyer has stock in Eli Lilly. |
| No disclosure on file | |
| Simon Duchesne, PhD (CRULRG) | Dr. Duchesne has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Qynapse SAS. Dr. Duchesne has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Nature Group. Dr. Duchesne has received stock or an ownership interest from Qynapse SAS. Dr. Duchesne has received intellectual property interests from a discovery or technology relating to health care. |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Gary Zammit | Gary Zammit has received personal compensation for serving as an employee of Clinilabs, Inc.. Gary Zammit has received stock or an ownership interest from Clinilabs, Inc. Gary Zammit has received stock or an ownership interest from Sleep Disorders Institute. Gary Zammit has received stock or an ownership interest from Home Sleep and Respiratory Care. |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Timothy L. Grant, MD (Neuroscience Consultants) | No disclosure on file |
| Russell Rosenberg (Neurotrials Research) | Mr. Rosenberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. The institution of Mr. Rosenberg has received research support from Neurotrials Research. |
| No disclosure on file | |
| Hong Sun | No disclosure on file |